Member Info for neilin62

Second trade dropped of the post:
2022-02-24T15:06:09.000 GBX 2.6 6300000 163800 Off-Book XOFF P ECHO
Neil

Countingcards,
I don't know where you are seeing those timestamps, but the official trades as listed by London Stock Exchange is as below with publication venue being ECHO, and tie up with the times shown here on LSE
Note, just the 2 trades shown
2022-02-24T15:14:10.110 GBX 2.6 76923 1999.998 Off-Book XLON P XLON
2022-02-24T12:45:00.000 GBX 2.6 6300000 163800 Off-Book XOFF P ECHO
2022-02-24T15:10:15.457 GBX 2.584 100000 2584 Off-Book XLON P XLON
2022-02-24T15:10:14.313 GBX 2.584 250000 6460 Off-Book XLON P XLON
2022-02-24T15:10:11.267 GBX 2.584 10000 2584 Off-Book XLON P XLON
2022-02-24T15:09:06.310 GBX 2.584 20000 516.8 Off-Book XLON P XLON
Neil

Generally, when you see 2 trades followed by a -ve trade, it is indicative of a short position opening / closing.
The key is the time stamp. If you look, two of them were exactly the same time stamp, but unusually, the third was different. Could just have been notified late.
Neil

Cant post the link, but if anyone wants a really good read into the UK's green transformation and battery materials requirements, type the subject title in google and enjoy.
Neil

Just one bit of info i thought i would share....
I know a couple of posters queried the other test that the NHS is evaluating. I pointed this to being the Galleri test.
I am aware that the NHS trial is just one of a number of trials that Grail have enacted.( they are doing these to get the same approvals we are chasing)
From the data received, i can tell you that our test absolutely knocks spots of theirs.
As an example, one study has shown that Galleri only detected 39% of stage 1 cancers.
In another, false positive tests came back at 49%
To put it another way, you would have more accuracy if you called heads or tails on a coin toss!
Lots of literature is out there saying " can detect 50 cancers, high accuracy, specific targetting" etc, etc. When you look at specific data, it suddenly doesn't look quite as good as the headline would imply.
Getting into NHS first and foremost will be the overriding priority. We already have the proof of concept proven in laboratory tests on a prototype using a polyclonal antibody. We are now modifying the test for monoclonal antibody, so we can demonstrate repeatability, and a high throughput / low base cost for commercial use in hospital environment.
Neil

Hi Widglide
Glad to see you are a bit more positive and hope it works out for you. ( I am sure it will, you know my stance on this ) More news is yet to come on a number of fronts.
I am wondering if we will fastrack our kit into NHS by way of a slight deviation on the CE marking process. To get it in quicker, we could go down the route of UKCA which is the new regulatory body for UK only market following Brexit. (The CE mark doesn't actually lapse yet, as it has been extended due to Covid impacting on the full application of MDR regulations)
It would get us there quicker. As we are looking at our test kit being registered as a Form B device, this will also mean that the requirements for verification aren't as onerous as other devices. Then we can carry on with CE mark for Europe, and FDA for USA.
We are looking at utilising the submission of retrospective testing data for CE approval, and FDA clearance. Again, if accepted, this would give a quicker path to approvals.
It's all coming.
Neil

Schlum/Islandgirl,
The test you are referring to is the Galleri test.
It is being evaluated by the NHS, BUT it is not the same as our test, so no real comparison. Galleri is specifically aimed at already "at high risk" individuals, specifically in the 50 - 77 year age range. It does not have FDA clearance, nor is it CE approved. It is being trialled on a Clia basis. Our test is being developed to detect cancer at a much earlier stage, and not restricted to known, at risk groups, or specific age groups. We discussed this previously when it was announced. If you look back at some posts i made in September they give more detail.
Neil

There's no "maybe" about it RiseOfThePorper,
Our focus is initially getting our test kit into NHS.
A further development later, will be to make an adjustment to the test in order that it can be rolled out to Primary Health Care providers, with the goal being that it can be used by your GP.
Neil

mcadder,
"unfortunately was a sell"
yes, but.....I have been looking at the trades today.
I initially thought that the 15.5 million may have been just been bought up by general trades.
The trade was time stamped at 11:39:28.577 on X LON
However, there is a corresponding trade, 28 seconds later which was time stamped at 11:39:56.217, but this one was on ECHO.
I may be wrong, but i think that was a straight buy/sell between 2 parties.
We should know either way on Tue/Wed next week, but even if it was just a sell, it had very little effect on the share price.
Neil

Hope you follow this chain of events......
Enterprise Ventures were aquired by Mercia Asset Management.
Mercia Asset Management were previously known as Finance Yorkshire.
Part of Finance Yorkshire's fund portfolio was a sector known as Finance Yorkshire Seedcorn Fund.
Yorkshire Seedcorn Fund were the providers of the initial capital (and later a small unsecured loan £10k) back in the days of York University when the company first registered.
All that has happened is that they have sold off 15.5 million shares, and still hold 7,437,410 bringing them below the 3% threshold for reporting.
They sell off assest in this way quite regularly - there is nothing untoward about it, it's how they generate their investment funds. You can be sure that they have made a tidy profit, even selling when they did.
Neil

Not IF it gets approved in my opinion, but WHEN it gets approved. And not next year either. I am expecting an RNS detailing approval in the very near future.
No need for a raise either. We are fully funded until end of 2022, and the recent agreement means further income for us. There are still other interests that we have that could provide even more revenue streams.
Any further funding required, would be for other projects in the pipeline, which we would be looking at towards the end of the year.
Neil

Great RNS, Posted previously about the expected agreement with China, given Allan Symm's previous dealings with them.Still more to come in my opinion, with companion diagnostics, licensing agreements, etcBut the real turning point will be the RNS that tells us about CE and / or 501(k) approval.Neil

Interesting 5 million *sell* after the bell.
5 million shares equates to just short of 2%.
As the reporting threshold is 1%,
if the seller is any of the "significant shareholders" then this will definitely be a TR1 on Wed/Thur
If not, then the seller will surely be out or very nearly by now, as much more would have been in TR1 territory if they have any more.
London South East showing 89 trades today, with a volume of 16,284,649
London Stock Exchange official figures are 94 trades with a volume of 17,475,797
So a discrepancy of 5 trades, and shares traded of 1,191,148
Be interesting to see what the SP does in the morning.
Neil

Looks like a short closing @ 1,293,750 as there are 3 trades matching with exactly the same time stamp.
Also looks like there could possibly be a 200,000 in there too with same time, but one more 200k to come to match up, unless it will be put through late, or a mix of smaller trades to disguise.
Lot more activity than normal today. Wonder if news in the pipeline?
Widglide, appreciate you are still angry about PSL/BOU and the way we were let down. I still maintain my opinion that this is going places, and to back up my theory,
one of the bigger buys was mine (again) as i am slowly building up to a sizeable holding.
But as i always say, only my opinion, and not advice.
Neil

The money raised on the original IPO and placing gave us funding through to end of 2022.
However, don't forget the following income streams:
1. Potential payment for production of antibodies and reagents plus further royalties for sales and services with ICCAMT & ILT on completion of the MOU through to contract.
2. Up to £1million in development fees with SGSC
3. Potential royalties of up to £5million from commerciaiization of AZD1656
1. Any other licensing deals that may be being secured.
So pretty well funded for the foreseeable future.
Neil

That trade was a transfer between 2 parties, but made by the same investment advisor, who acted on behalf of both parties (as buyer from party No1 and seller to party No1)
The trade was not made on the London Stock Exchange, but on a different venue. In this case, it was ECHO.
It was done as a P-ACTX trade which is an agency cross trade.
What it tells us is that the advisor knew someone who owns a lot of shares (institutional?) wanted a sell, but he / she also had a client wanting to take the lot in one go!
Someone appears to be building up their holding
Neil

I would bet that the £73k was a buy.
Currently jumped up 5.26%
Neil

To all the long term / old BOU / PSL holders, and the newer faces:
I hope you all have a Very Happy Christmas and a Healthy and prosperous New Year, and that our time will come.
There is still much news to follow, and i am confident this will turn out well.
Wideglide; I know that you are feeling let down, and i especially wanted to say that i hope you will see better times coming with this.
When all seemed lost last year, i was confident that we would relist when we were suspended. After the initial red herring with Coeur, I was confident that we would be in the Bio sector. I was confident that Allan Syms would feature highly in the new company. I mentioned that i expected agreements on licensing deals, and that we would enter companion drug deals, and an interest in China.
I am also confident that we are going to make it big. So confident, that despite being well down on my PSL / BOU investment, i have been steadily buying a sizeable part of this company, but that is not to be taken as advice....only what i believe. As i have said previously, the Bio Sector takes time, (but it won't be as long as the timescales some have mentioned) and when all is commercialised, and we have our approval(s) i expect to see a take over at a point in the future. As i said a while back, i am not in this to make a few thousand quid - i am expecting a sizeable return.
All the best everyone, and keep safe.
Neil

*1% increments"

Unfortunately, i don't think that is the case.
YORKSHIRE SEEDCORN FUND was a division of Finance Yorkshire, (later Enterprise Ventures who were acquired by MERCIA)
It looks like all that has happened is they have reduced their original holding from 24,437,410 (9.37%) to 23,437,410 which is just below the 9% mark. Because any holding above 5% is reportable, at 15 increments,they have now dropped to a point where a report was required.
Neil